Earlier treatment with Tremfya resulted in higher clearance rates in moderate to severe psoriasis patients.
Janssen has presented the data from Phase 3b GUIDE study, a trial intended to assess the effect of early intervention of Tremfya (guselkumab). The data showed that some 'super responders' to Tremfya who received a 16-week maintenance dose had non-inferior effectiveness compared to an 8-week dosing interval.
The GUIDE study aimed to determine the efficacy of the prolonged dose of Tremfya in super respondents. In part one of the study, patients who received Tremfya until week 20 and had PASI 0 from week 20 to 28 were considered super respondents. In the second part of the study, super respondents were treated with Tremfya at either 8-week or 16-week intervals. In the third phase of the study, patients were followed up until week 220 and were treated only if PASI worsened to greater than 5.
Further, the new analysis from the VOYAGE 1 and VOYAGE 2 trials demonstrated improved quality of life measured by the Dermatology Life Quality Index (DLQI) score of 0 or 1, persistent skin clearance, and durable responses through week 252 in patients who achieved either >90% improvement in PASI or 100% improvement in PASI.
Cosentyx demonstrated relief from clinical signs and symptoms of moderate-to-severe hidradenitis suppurativa
Novartis presented the data from SUNSHINE and SUNRISE trials, demonstrating efficacy versus placebo. Novartis announced that it is planning to present long-term results in 2023. Currently, Cosentyx (secukinumab) showed sustained efficacy up to 52 weeks in patients with HS.
The two trials showed that a higher percentage of patients achieved a Hidradenitis Suppurativa Clinical Response (HiSCR) versus a placebo. When 300 mg of Cosentyx was administered every two weeks, there was a significant improvement versus placebo in the SUNSHINE and SUNRISE trials (45.0% vs. 33.7% and 42.3% vs. 31.2%, respectively).
BMS presented long-term data of Sotyktu in moderate-to-severe psoriasis
Bristol Myers Squibb announced the long-term of Sotyktu (deucravacitinib) in patients with moderate-to-severe plaque psoriasis.
The company has presented the data from the POETYK PSO-1 trial, demonstrating the efficacy of Sotyktu versus placebo and Otezla (apremilast).
In the POETRY PSO-1 trial, 171 out of 262 patients on Sotyktu achieved Psoriasis Area and Severity Index (PASI 75) at week 16 and maintained it until 112 weeks. After 112 weeks of treatment, PASI 75 was 82.47%, PASI 90 was 55.2%, and static Physician's Global Assessment (sPGA) 0/1 was 66.5%.